Acetaminophen Transfer Across the Placenta and the Assessment of Fetal Well-being

NCT ID: NCT01211912

Last Updated: 2014-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study has two aims:

1. to evaluate placental transfer of acetaminophen from mother to baby transplacentally given from 30 minutes to 24 hours prior to cesarean delivery (34 patients)
2. to understand the impact of maternal acetaminophen use on fetal movement and breathing (20 patients)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fetal Testing Transplacental Transfer of Acetaminophen

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1 (20 patients)

Pregnant women will be given a single dose of 1000 mg of acetaminophen orally after a baseline ultrasound and 60 minutes before a repeat ultrasound.

Group Type EXPERIMENTAL

Arm 1 (20 patients)

Intervention Type DRUG

Acetaminophen 1000 mg by mouth once

Arm 2 (34 patients)

Pregnant women will be given a single dose of 1000 mg of acetaminophen orally 30 minutes to 24 hours before a scheduled cesarean section.

Group Type EXPERIMENTAL

Arm 2 (34 patients)

Intervention Type DRUG

Acetaminophen 1000 mg by mouth once

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arm 1 (20 patients)

Acetaminophen 1000 mg by mouth once

Intervention Type DRUG

Arm 2 (34 patients)

Acetaminophen 1000 mg by mouth once

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tylenol Tylenol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant females
* Age 18-44
* Any race
* Any parity
* Singleton Gestations
* Weight between 60-90 kg

Exclusion Criteria

* Acetaminophen Allergy
* Contraindication to Acetaminophen Use
* Chorioamnionitis
* Preeclampsia
* Diabetes Mellitus
* Placental Abruption
* Placenta Previa
* Fetal Anomaly
* Intrauterine growth restriction (IUGR)
* Multiple Gestations
* Maternal Medical Disease
* Acetaminophen use in the last 3 days
* Plan to donate or bank fetal cord blood
Minimum Eligible Age

18 Years

Maximum Eligible Age

44 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mayo Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Brian C. Brost, M.D.

PI

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brian C Brost, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10-003283

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Delayed Cord Clamping and Use of Oxytocin
NCT02618499 TERMINATED PHASE3
Vaginal Progesterone in Twins With Short Cervix
NCT01812239 WITHDRAWN PHASE2/PHASE3